The overproduction of E. coli in the gut, which causes diarrhea or intestinal inflammation, can be attributed to the availability of sialic acid, found in the proteins of the intestinal mucosa, they discovered. To use sialic acid to multiply, E. coli uses the enzyme sialidase, released by other intestinal bacteria.
From there, the researchers discovered that when people take a sialidase inhibitor, the E. coli can’t multiply excessively and therefore the disease symptoms were alleviated. Flu-fighting medications serve as sialidase inhibitors.
“Derivatives of known flu agents such as Tamiflu and Relenza could therefore also be used for inflammatory intestinal diseases, which opens up new therapeutic possibilities,” said Thierry Hennet, a professor from the University of Zurich.
More articles on infections:
Respiratory infections may spread via personal clothing, study finds
Study findings support giving flu vaccines to the elderly
Flu vaccines effective for 6 months, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
